




RealRate

PHARMACEUTICAL 2022

BeiGene Ltd.
Rank 126 of 475





RealRate

PHARMACEUTICAL 2022

BeiGene Ltd.
Rank 126 of 475



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of BeiGene Ltd. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 8.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 21%, being 297% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	7,613,880
Cost of Goods Sold	164,906
Intangible Assets	46,679
Liabilities, Current	1,599,555
Liabilities, Non-Current	803,407
Other Assets	397,785
Other Compr. Net Income	11,008
Other Expenses	-24,484
Other Liabilities	0
Other Net Income	147
Property and Equipment	587,605
Research and Development	1,459,239
Revenues	1,176,283
Selling, General and Administrative Expense	990,123

Output Variable	Value in 1000 USD
Assets	8,645,949
Liabilities	2,402,962
Expenses	2,589,784
Stockholders Equity	6,242,987
Net Income	-1,413,354
Comprehensive Net Income	-1,407,850
Economic Capital Ratio	21%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai